EPA from VASCEPA Doubles Omega-3 Levels in Colorectal Tissue Within 12 Weeks

Colorectal cancer remains one of the leading causes of cancer mortality worldwide, and chronic inflammation driven by omega-6 fatty acids is thought to promote tumor development. Shifting the tissue balance toward anti-inflammatory omega-3 fatty acids is a compelling preventive strategy, but whether oral supplementation can meaningfully alter fatty acid composition in colorectal tissue — where it matters most — has not been well established.

The PREPARE trial enrolled 81 patients with a recent history of colorectal adenomas, a known precursor to cancer. Participants received 4g/day of icosapent ethyl (IPE, sold as VASCEPA), a pharmaceutical-grade purified eicosapentaenoic acid (EPA) ethyl ester, for 8–12 weeks. Colorectal biopsies were collected before and after treatment via flexible sigmoidoscopy, and fatty acid composition was measured using gas-liquid chromatography.

Results were striking. Total marine omega-3 PUFA in colorectal tissue increased from a median of 2.10% to 5.21% — a 2.4-fold increase. EPA itself surged nearly sixfold, representing the largest individual change. Omega-6 PUFA modestly declined, and the omega-3 to omega-6 ratio improved by 2.58-fold. Notably, cumulative IPE dose — not just daily dose — correlated with EPA tissue incorporation, suggesting duration of therapy matters. Participants with lower baseline dietary EPA intake appeared to benefit most, though this interaction was not statistically significant.

These findings confirm that oral IPE effectively delivers EPA into the colorectal tissue microenvironment, not merely into circulation. This is a critical mechanistic step: if omega-3 enrichment at the tissue level reduces pro-inflammatory signaling, it could suppress adenoma recurrence or progression to carcinoma.

Caveats include the single-arm design without a placebo control, the relatively small sample size, and the fact that tissue fatty acid changes are a surrogate endpoint — whether they translate to reduced colorectal cancer risk remains to be demonstrated in larger trials.